-
Saudi Arabia and other countries adhere to the position of reducing production, crude oil rebounds by more than 1%
Time of Update: 2023-01-05
Saudi Arabia firmly took the position of OPEC+ production cuts, and the United Arab Emirates also denied rumors of production increases, and international oil prices closed higher on Tuesday.
-
Express psoriasis symptoms are significantly alleviated! Phase 1 trials of oral IL-17 inhibitors have yielded positive results
Time of Update: 2022-10-20
▎WuXi AppTec content team editor A few days ago, DICE Therapeutics announced that its oral inhibitor DC-806, which targets IL-17, has achieved positive results in a phase 1 clinical trial 。 These resu
-
Weight loss of up to 10 kg in 6 weeks, Pfizer two oral GLP-1 receptor agonists clinical results are positive
Time of Update: 2022-10-01
▲PF-07081532 dose-dependent type reduces patient weight (Source: Pfizer official website)The trial results released today also include the results of a 16-week phase 2b clinical trial of danuglipron in the treatment of patients with type 2 diabetes.
-
Express 75% of patients maintained complete remission after one year, with positive Phase 2
Time of Update: 2022-06-17
▎WuXi AppTec Content Team Editor Today, CG Oncology announced that the company's oncolytic virus therapy CG0070, in combination with Merck's anti-PD-1 antibody Keytruda, has been approved in a Phase 2 clinical trial for the treatment of non-muscle invasive bladder cancer.
-
Yifang Bio's new KRAS G12C inhibitor achieved positive results in Phase 1 clinical trials
Time of Update: 2022-05-23
Transfer from | Medicine GuanlanRecently, Yifang Bio announced the first clinical data of its oral KRAS G12C inhibitor in cancer patients .
This time, Yifang Bio presented its Phase 1 clinical data of its oral KRAS G12C inhibitor at the AACR .
-
siRNA therapy can reduce important risk factors of cardiovascular disease by 98%. Phase 1 clinical results of siRNA therapy are positive
Time of Update: 2022-05-02
Silence Therapeutics announced today that its investigational small interfering RNA (siRNA) therapy SLN360 has achieved positive results in a single-dose escalation Phase 1 clinical trial .
References:[1] Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a).
-
patients with advanced PD-L1 positive (CPS≧1) gastric/gastroesophageal junction (GEJ) cancer (KEYNOTE-063)
Time of Update: 2022-04-24
The study showed that the KEYNOTE-063 study results were consistent with the global KEYNOTE-061 study results, and pembrolizumab did not improve the efficacy of Asian PD-L1-positive gastric/gastroesophageal junction (GEJ) cancer patients compared with second-line paclitaxel .
-
J INTERN MED: Symptoms and functional impairment at 1 year in SARS-CoV-2 positive and negative individuals
Time of Update: 2022-04-19
5% of SARS-CoV-2-positive individuals reported impaired function at 12 months compared with 6.
1-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals .
134821-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals leave a comment here
-
for breast cancer patients with ER-positive low expression (IHC 1%-10%)
Time of Update: 2022-04-15
Recently, the journal Cancer published the results of a retrospective propensity-matched analysis from Fudan University Cancer Hospital , mainly evaluating the use of short-course (2-3 years) adjuvant in patients with ER-positive low-expression (IHC 1%-10%) breast cancer.
-
The world's first first-line treatment of SCLC with positive results of PD-1 inhibitor data announced!
Time of Update: 2021-12-29
The ASTRUM-005 study is a randomized, double-blind, international multi-center, phase III clinical study that evaluated slulimumab and placebo combined with chemotherapy for the treatment of previously untreated extensive-stage small cell lung cancer (ES-SCLC) Patient effectiveness and safety .
-
Twist Bioscience is now selling a synthetic RNA positive control for the new crown mutant strain
Time of Update: 2021-12-24
South San Francisco, California, USA--(Business Wire)--December 15, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers obtain A successful company, the company today announced the launch of a synthetic RNA positive control for the SARS-CoV-2 mutant strain Omi Keron (B.
-
Express delivery of 100% of patients achieved complete remission, and the Phase 2 clinical results of the oncolytic virus/PD-1 antibody combination are positive
Time of Update: 2021-12-07
▎The content team editor of WuXi AppTec recently, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, combined with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer , These patients did not respond to BCG treatment .
-
100% of patients achieve complete remission of oncolytic virus/PD-1 antibody combination Phase 2 clinical results are positive
Time of Update: 2021-12-02
A few days ago, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, in combination with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer.
-
Using custom AAV capsids to improve drug delivery ophthalmic gene therapy Phase 1 trial results are positive
Time of Update: 2021-11-05
On October 10, 2021, 4D Molecular Therapeutics (4DMT) announced that its intravitreal injection of gene therapy 4D-125 has achieved a positive mid-term in a phase 1/2 clinical trial for patients with advanced X-linked retinitis pigmentosa (XLRP) Safety and clinical activity data .
-
Express gene editing to create "ready-to-use" CAR-T therapy, phase 1 clinical trial results are positive
Time of Update: 2021-10-21
▎The content team editor of WuXi AppTec today, CRISPR Therapeutics announced that the allogeneic CAR-T cell therapy CTX110, modified with CRISPR gene editing technology, has achieved positive safety and efficacy in a phase 1 clinical trial for the treatment of CD19-positive B-cell cancers Result .